Founded in 1965, NMS Group is one of Europe's largest oncology R&D organizations, focusing on the discovery and early development of oncology drugs. Apart from its specialization in drug discovery, NMS is the only player that offers a turnkey through its integrated supply chain, from the pre-clinical phase of research to the First-In-Human clinical phase, concluding with the production and packaging phase of finished drugs. It has more than 400 employees, with over 100 of them being top scientists.

NMS is the best pharmaceutical R&D center in Italy. It has successfully developed eight original drugs including ADRIAMYCIN®, Ellence® and Aromasin®, and has extensive experience in target discovery and validation, kinase research and antibody-coupled drug platforms.